The Pharma Data

MAY 18, 2021

This business developed positively in the Europe/Middle East/Africa region and in Latin America, partly as a result of higher prices, whereas it shrank in North America, in part due to a license expiration. Notes: The following tables contain the key data for the Bayer Group and its divisions for the first quarter of 2021.

Sales 40

Sales Production Marketing Containment 40

The Pharma Data

JANUARY 4, 2021

. Kiromic’s deep understanding of the tumor micro environment (TME) and the tumors’ escape and masking mechanisms led to development of a promising platform for chimeric antigen receptor therapy (CAR-T). We believe our allogenic CAR-T platform is significantly stronger with chPD1 target licensed from Longwood University.

In-Vivo 40

In-Vivo Development Immune Response Big Data 40

The Pharma Data

AUGUST 3, 2021

Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. Business Development/Other Developments. In the second quarter of 2021, the company recognized acquired in-process research and development charges of $25.0

Antibody 52

Antibody Sales Development Production 52

The Pharma Data

NOVEMBER 5, 2020

Collegium will grant Teva a license to market its generic version of Xtampza ER in the United States beginning on or after September 2, 2033 (subject to U.S. This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. FDA approval, and customary exceptions).

Production 52

Production Marketing Sales Manufacturing 52

The Pharma Data

MAY 4, 2021

Pfizer’s Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, which had been reported within the results of the Upjohn Business (4) in the first three quarters of 2020 , is now included within the Hospital therapeutic area for all periods presented. 7) BNT162b2 has not been approved or licensed by the U.S.

Vaccine 40

Vaccine Vaccination Production Sales 40

The Pharma Data

NOVEMBER 15, 2020

Prior to Celgene, she held leadership roles in marketing, sales and new business development from 2002 to 2011 at Johnson & Johnson. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Before that, Ms.

Clinical Trials 40

Clinical Trials Clinical Trials Production Trials 40

The Pharma Data

NOVEMBER 5, 2020

The FDA accepted for priority review, with a target action date of February 28, 2021 , the supplemental Biologics License Application (sBLA) for Libtayo ® (cemiplimab) as monotherapy to treat patients with first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) with ?50% Corporate and Business Development Update.

Sales 40

Sales Production Manufacturing Antibody 40

The Pharma Data

AUGUST 6, 2020

announced that the companies submitted the Biologics License Application (BLA) to the U.S. The information contained on, or that may be accessed through, our website or social media channels are not incorporated by reference into, and are not a part of, this document. In June, the company and Acceleron Pharma Inc. Regulatory.

Production 52

Production Branding Marketing Containment 52

Pharmaceutical Technology

FEBRUARY 16, 2023

The document contains detailed information on the suppliers and their product offerings, alongside contact details to aid your purchasing or hiring decision.

Engineer 130

Engineer Manufacturing Containment Production 130

The Pharma Data

DECEMBER 23, 2020

Govindarajan, Managing Director, Aurobindo Pharma Limited , said: “We are proud to partner with COVAXX in developing the first-ever synthetic peptide-based vaccine to combat the COVID-19 pandemic. This vaccine has immense potential in eliminating shedding, and hence containing, the spread of the pandemic.” ” .

Vaccination 52

Vaccination Vaccine Development Manufacturing 52